Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC W23 digital CBT-I sleep therapy at $60/month with 50% better results than sleeping pills; $6.5M total ($6M Initialized/YC/Goodwater seed Feb 2024) treating chronic insomnia psychologically competing with Sleepio.
Stellar Sleep is a United States-based digital sleep therapy platform — backed by Y Combinator (W23) with $6.5 million in total funding including a $6 million seed in February 2024 led by Initialized Capital with Y Combinator, Lombardstreet Ventures, Switch Ventures, Moonfire Ventures, Scrum Ventures, 8vdx, and Goodwater Capital — providing chronic insomnia sufferers with a $60/month mobile app that delivers CBT-I (cognitive behavioral therapy for insomnia), acceptance and commitment therapy, and motivational interviewing through a structured program clinically validated to be 50% more effective than sleeping pills for long-term insomnia resolution. Founded in 2023, Stellar Sleep treats the root psychological and behavioral causes of insomnia rather than masking symptoms with pharmaceutical or supplement approaches.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.